Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Debt to Equity (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Debt to Equity for 15 consecutive years, with -$0.37 as the latest value for Q4 2024.

  • On a quarterly basis, Debt to Equity rose 87.53% to -$0.37 in Q4 2024 year-over-year; TTM through Dec 2024 was -$0.37, a 87.53% increase, with the full-year FY2024 number at -$0.37, up 87.53% from a year prior.
  • Debt to Equity was -$0.37 for Q4 2024 at Plus Therapeutics, up from -$0.64 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $131.55 in Q1 2020 to a low of -$2.95 in Q4 2023.
  • A 5-year average of $7.48 and a median of $0.62 in 2022 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: surged 3430.72% in 2020, then plummeted 452.43% in 2023.
  • Plus Therapeutics' Debt to Equity stood at $2.09 in 2020, then plummeted by 78.11% to $0.46 in 2021, then surged by 82.89% to $0.84 in 2022, then tumbled by 452.43% to -$2.95 in 2023, then skyrocketed by 87.53% to -$0.37 in 2024.
  • Per Business Quant, the three most recent readings for PSTV's Debt to Equity are -$0.37 (Q4 2024), -$0.64 (Q3 2024), and -$0.43 (Q2 2024).